The Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

(2020) Xueting Yao et al.   CLINICAL INFECTIOUS DISEASES

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The COVID-19 Pandemic and Mayo Clinic Proceedings

(2020) Karl A. Nath   MAYO CLINIC PROCEEDINGS

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2020) Mayla Gabriela Silva Borba et al.   JAMA Network Open

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

(2018) Clotilde Chatre et al.   DRUG SAFETY

Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy

(2012) Andrea Frustaci et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine

(2007) Philippe Stas et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY